1. Introduction

molecules

Molecules

1420-3049

MDPI

10.3390/molecules171112961

molecules-17-12961

Article

4-(1H-Pyrazol-1-yl) Benzenesulfonamide Derivatives: Identifying New Active Antileishmanial Structures for Use against a Neglected Disease

Marra

Roberta K. F.

1 Bernardino

Alice M. R.

1 * Proux

Tathiane A.

2 Charret

Karen S.

3 Lira

Marie-Luce F.

2 Castro

Helena C.

2 * Souza

Alessandra M. T.

4 Oliveira

Cesar D.

1 Borges

Júlio C.

1 Rodrigues

Carlos R.

4 Canto-Cavalheiro

Marilene M.

3 Leon

Leonor L.

3 Amaral

Veronica F.

2 *

1 Programa de Pós-graduação em Química, Instituto de Química, Universidade Federal Fluminense, Outeiro de São João Baptista, Niterói, RJ, 24020-150, Brazil; Email: katlenfusco@bol.com.br (R.K.F.M.); posgraduacaouff@vm.uff.br (C.D.O.); juliusborges@yahoo.com.br (J.C.B.) 2 Programa de Pós-graduação em Ciências e Biotecnologia PPBI, Instituto de Biologia, Universidade Federal Fluminense, Outeiro de São João Baptista, Niterói, RJ, 24020-150, Brazil; Email: tathimir@hotmail.com (T.A.P.); marie.biouff@gmail.com (M.-L.F.L.) 3 Laboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, RJ, 21040-900, Brazil; Email: karenbio@hotmail.com (K.S.C.); mcantocavalheiro@hotmail.com (M.M.C.-C.); lleon@ioc.fiocruz.br (L.L.L.) 4 Faculdade de Farmácia, ModMolQSAR, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-590, Brazil; Email: amtsouza2@yahoo.com.br (A.M.T.S.); rangelrodrigues2003@yahoo.com.br (C.R.R.)

* Authors to whom correspondence should be addressed; Email: gqolice@vm.uff.br (A.M.R.B.); hcastrorangel@yahoo.com.br (H.C.C.); veronicadoamaral@gmail.com (V.F.A.); Tel.: +55-21-2629-9954 (H.C.C.).

01 11 2012

11 2012

17 11 12961 12973 30 08 2012 08 10 2012 12 10 2012

2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Leishmaniasis is a neglected disease responsible for about 56,000 deaths every year. Despite its importance, there are no effective, safe and proper treatments for leishmaniasis due to strain resistance and/or drug side-effects. In this work we report the synthesis, molecular modeling, cytotoxicity and the antileishmanial profile of a series of 4-(1H-pyrazol-1-yl)benzenesulfonamides. Our experimental data showed an active profile for some compounds against Leishmania infantum and Leishmania amazonensis. The profile of two compounds against L. infantum was similar to that of pentamidine, but with lower cytotoxicity. Molecular modeling evaluation indicated that changes in electronic regions, orientation as well as lipophilicity of the derivatives were areas to improve the interaction with the parasitic target. Overall the compounds represent feasible prototypes for designing new molecules against L. infantum and L. amazonensis.

pyrazoles benzenesulfonamide Leishmania cytotoxicity in silico evaluation

1. Introduction

Leishmaniasis is a parasitic disease with severe morbidity and mortality rates. According to the World Health Organization, there are two million infected people and approximately 56,000 deaths reported every year [1,2]. Ninety percent of the visceral leishmaniasis (VL) cases occur in Brazil, India, Nepal, and Bangladesh [1,2]. Thus leishmaniasis is included in the WHO neglected diseases group since the pharmaceutical industry has little commercial incentive to invest in new treatment options.

Leishmania spp. causes a broad spectrum of infectious diseases ranging from self-healing cutaneous ulcerations to progressive and lethal visceral infection. L. amazonensis infection in humans can be associated with a spectrum of disease manifestations, depending on the immune status of the host or other external factors [3]. Currently the epidemiological pattern of Leishmania spp. [e.g., L. amazonensis and L. infantum (L. chagasi syn.)] is changing, with a tendency to urbanization and geographic expansion. Despite the high worldwide prevalence, few advances were made in the treatment of this disease [4,5,6,7,8,9]. There are no vaccines for Leishmaniasis and vector control is complex [2,8].

Currently, the drugs used for leishmaniasis treatment present many disadvantages, including serious clinical side effects such as nephrotoxicity, hepatotoxicity and cardiac arrhythmia, whereas the emerging strain resistance to available drugs has also decreased the treatment options [7]. Resistance to pentavalent antimonials is generating a problem in the treatment of visceral leishmaniasis in India whereby naturally resistant parasites have higher virulence than susceptible L. donovani [9]. Some additional drugs including pentamidine (aromatic diamine), amphotericin B (polyene antibiotic) and miltefosine (alkyl phopholipid) were introduced as substitutes in chemotherapy but without complete efficacy [4]. Currently the pentavalent antimonials are the first line treatment employed in Brazil, followed by pentamidine and amphotericin B [10].

The leishmaniasis treatment restrictions and the resistant strains point to the urgent need for new therapeutic options. Therefore, several reports regarding natural and synthetic new antileishmanial compounds have been described [4,7], including some by our group [11,12,13]. Literature about the pyrazole nucleus chemistry has reported a broad spectrum of pharmaceutical activities [14]. Similarly, sulfonamides show different biological activity profiles, including antibacterial [15], anti-HIV [16], anti-Trypanosome [17,18] and anti- Leishmania properties [17,18,19,20].

Recently, we reported new pyrazole carbohydrazide derivatives with in vitro antiparasitic activity against L. amazonensis promastigotes and, to a lesser extent, L. braziliensis and L. infantum (chagasi syn.), with no toxicity to murine macrophages [11]. The literature also described that mice experimentally infected with L. amazonensis and treated with pyrazole carbohydrazide derivatives controlled the evolution of both footpads cutaneous lesions and dissemination of parasites to draining lymph nodes [6]. In addition the evaluation of pyrazole carboximidamide derivatives also revealed potential in vitro activity against L. amazonensis [12].

A therapy using an anti-inflammatory drug with antileishmanial properties, lower toxicity, cost, side effects and patient compliance may be very advantageous [6]. Previous reports from our laboratory described the in vitro and in vivo activity of pyrazoles against Leishmania parasites [6,11,12,13]. In this work we describe the synthesis of a new pyrazole family exploring this time the addition of a sulfonamide group. Thus we evaluated the activity of these 4-(1H-pyrazol-1-yl)benzenesulfonamide derivatives against Leishmania infantum and L. amazonensis and their cytotoxicity profile towards mammalian cells. We also performed a structure-activity relationship (SAR) evaluation of these derivatives using a molecular modeling approach.

2. Results and Discussion 2.1. Chemistry

This work examined the functionalization of the core 1-phenylpyrazoles with a sulfonamide due to the group’s antileishmanial profile previously described in the literature [11]. The 4-(4-bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)benzenesulfonyl chloride (1) derivative was obtained in good yield by a regioselective electrophilic aromatic substitution reaction between the corresponding 1-phenylpyrazole derivative and chlorosulfonic acid. The compound 4-(5-chloro-3-methyl-1H-pyrazol-1-yl)phenylamine (2) was prepared by nitration of the corresponding 1-phenylpyrazole derivative, followed by reduction with iron powder and ammonium chloride.

The target compounds 3a–g could be easily prepared with these key intermediates in hand through substitution reactions between the sulfonyl chloride moiety and amino intermediates [11,17]. Sulfonyl chlorides are electrophilic reagents that react readily with primary and secondary amines, such as the NH₂ of the benzene ring as shown in Scheme 1.

molecules-17-12961-scheme1_Scheme 1

Scheme 1

Synthesis of 4-(1H-pyrazol-1-yl)benzenesulfonamide derivatives 3a–g based on the previous synthesis of 5-amino-1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazoles (A) and 1-aryl-1H-pyrazole-4-carboximidamides (B).

These reactions were rapid with no side products, according to the experimental data. All the synthesized compounds were obtained as solids, purified by recrystallization from ethanol and characterized by spectroscopic techniques (IR, ¹H-NMR and ¹³C-NMR) and elemental analysis. The IR spectra of the compounds showed the presence of the characteristic bands for SO₂ in the 1330–1630 cm⁻¹ range. In addition, the ¹H-NMR spectra of these compounds revealed the presence of a singlet amino (NH) peak and multiplets due to the aromatic protons.

2.2. Biological Evaluation

In this work we evaluated the biological effect of 4-(1H-pyrazol-1-yl)benzenesulfonamides derivatives 3a–g against both the L. infantum (L. chagasi syn.) and L. amazonensis promastigote forms and compared with them with pentamidine, a reference drug used in leishmaniasis treatment [4] similar to other reports in the literature [21,22,23]. Interestingly, 3b and 3e showed the best in vitro active profile against the infective L. amazonensis promastigotes forms (IC₅₀ = 0.070 mM and 0.072 mM, respectively) as well as against L. infantum (L. chagasi syn.) (IC₅₀ = 0.059 mM and 0.065 mM, respectively) as shown in Table 1.

molecules-17-12961-t001_Table 1

Table 1

Comparison of the antileishmanial (IC₅₀) effect against Leishmania spp. and the theoretical parameters evaluation of the molecular electronic properties of the new 4-(1H-pyrazol-1-yl)benzenesulfonamide series 3a–e, including the lowest unoccupied molecular orbital (LUMO) energy (eV), dipole (Debye), and Lipinski “rule of five” (molecular weight - Mw, number of hydrogen bound donor - HBD, or acceptor - HBA groups and lipophilicity - cLogP).

Compound	Antileishmanial activity				LUMO (Ev)	Dipole (Debye)	Lipinski “rule of five”
	(IC₅₀ = mM) ^a,b						Lipinski “rule of five”
	Leishmania infantum	S.I ^c	Leishmania amazonensis	S.I ^c			M_W	clogP	HBA	HBD
3a	0.228 ± 0.19	0.78	0.228 ± 0.33	0.78	−1.61	4.61
3b	0.059 ± 0.01	2.44	0.070 ± 0.02	2.05	−1.67	4.53	426.72	3.27	4	1
3c	0.123 ± 0.05	1.33	0.318 ± 0.59	0.51	−1.63	4.80	440.75	3.58	4	1
3d	0.099 ± 0.08	0.49	0.075 ± 0.01	0.65	−1.79	3.69	505.62	3.97	4	1
3e	0.065 ± 0.04	1.78	0.072 ± 0.05	1.61	−1.77	3.75	461.17	3.88	4	1
3f	0.138 ± 0.11	0.76	0.153 ± 0.22	0.68	−1.29	4.84	347.83	2.57	4	1
3g	0.149 ± 0.12	1.21	0.136 ± 0.054	1.33	−1.18	5.24	361.85	2.88	4	1

^a Mean of IC₅₀ (mM) ± S.D. for three determination; ^b Pentamidine was used as control drug (IC₅₀ = 0.062 and 0.021 mM; S.I = 0.87 and 2.57 respectively); ^c Selectivity index (SI): CC₅₀ drug/IC₅₀ drug.

L. infantum (L. chagasi syn.) is a strain of epidemiological importance [24] and responsible for the American visceral clinic form, whereas L. amazonensis has been implicated in cutaneous, mucosal, visceral and diffuse clinic forms of leishmaniasis [3]. Our biological data pointed to the potential of compounds 3b and 3e as active pyrazole structures containing sulfonamide groups for treating infections caused by these two Leishmania strains.

Our antileishmanial results with this new series are in agreement to the previous literature that shows the sulfonamide functionality can display antiparasitic [17,18,19,20] as well as antibacterial [13,25] and anti-viral HIV activities [16]. In fact the addition of the sulfonamide together with the bromide improved the antileishmanial activity of this series compared to our previous data from 5-amino-1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazoles derivatives [12] (Scheme 1). The activity against L. amazonensis of our new pyrazole series leads 3b and 3e, was slightly better than that of 1-aryl-1H-pyrazole-4-carboximidamides derivatives (lowest IC₅₀ = 0.105 mM) [12] but not than that of 5-amino-1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazoles (lowest IC₅₀ = 0.015 mM). The antileishmanial profile against L. infantum was also evaluated for 5-amino-1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazoles) [13]. Our results reveal this new series is active and better (3b and 3e IC₅₀ = 0.059 mM and 0.065 mM, respectively) compared to the non-active profiles of the 1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazole derivatives (lowest IC₅₀ > 0.500 mM).

Importantly, 3b showed an antileishmanial activity against both Leishmania species (IC₅₀ = 0.059 mM and 0.070 mM) and comparable to the effect of pentamidine on L. infantum (IC₅₀ = 0.062 mM) (Table 1). These data suggest that this derivative has the most potential for activity against L. infantum strains as an alternative to pentamidine. This is also reinforced by the cytotoxic evaluation using murine peritoneal adherent cells that showed 3b (CC₅₀ = 0.144 mM) and 3e (CC₅₀ = 0.116 mM) with lower cytotoxicity than pentamidine (CC₅₀ = 0.054 mM) (Figure 1). The selectivity index to L. infantum reinforced the fact that compound 3b (2.44) as better than pentamidine (0.87). Overall the in vitro results pointed to further explore these molecules in the in vivo tests as described for this and for other synthetic derivatives [25,26,27,28].

Figure 1

The experimental cytotoxicity (CC₅₀) using murine adherent peritoneal cells and the theoretical drugscore values of the new 4-(1H-pyrazol-1-yl)benzenesulfonamide series (3a−g) compared with pentamidine (Ptm), a current antileishmanial drug on the market. Higher values on both analyses suggest a good drug profile.

2.3. Molecular Modeling Data

In order to identify structural features important to this series’ antileishmanial profile we performed a structure-activity relationship (SAR) evaluation using a molecular modeling approach. The derivatives 3D-structures were constructed using the Spartan 10 program and the molecular properties were calculated as described in the Supplementary Material. Several parameters were evaluated, including the highest energy occupied molecular orbital (HOMO) and lowest energy unoccupied molecular orbital (LUMO). They are known as frontier orbitals or interacting molecular orbitals and a pair that lies closest in energy of any pair of orbitals in two molecules that interact, which allows them to interact most strongly. Therefore, it can be detected a correlation between the biological activity HOMO and LUMO energy and/or distribution as they may be directly involved in the interaction with the target [29,30].

The overall analysis pointed the lowest LUMO energy and dipole moment as well as the highest theoretical lipophilicity (cLog P) of the most active compounds as structural features that may contribute to the biological activity in this series. These features are probably related to the ability of penetrating the biological membranes of the parasite and interact with the biological target (Table 1).

According to our theoretical structural analysis the absence of the aromatic substituent affected the antileishmanial activity (i.e., 3a), in agreement to the literature [23]. The analysis of the minimum energy conformations of these compound showed that compounds 3b−e, 3f and 3g are coplanar, but with different spatial orientation (Figure 2). This is probably due to the retroisosterism of the sulfonamide, where the sulphur atom is linked directly to the aromatic ring in derivatives 3a–e, whereas for 3f and 3g, the nitrogen atom of the sulfonamide is connected to the ring (Figure 2). This variation led to different orientations that should influence the biological activity in this series as the spatial complementarity is a requirement to interact with the biological target (Figure 2).

Figure 2

Theoretical structural analysis of the new 4-(1H-pyrazol-1-yl)benzenesulfonamide series (3a–g) using a molecular modeling approach. Comparison of the highest occupied molecular orbital (HOMO) distribution (A) and of the structural orientation through the superposition (B) of the less (compounds 3a, 3f, 3g and 3c) and most active (3b–e) compounds. The theoretical analysis allowed pointing derivatives electronic regions (A) and orientation (B) that are probably related with a better interaction with the parasitic target (white boxes).

The stereo-electronic features evaluation suggests that the HOMO energy level (not shown) and molecular weight have no direct correlation with the observed activity (Table 1). However compounds 3b–e exhibit different HOMO distribution profiles, which probably orient the interactions with the parasitic target (Figure 2).

The analysis of the steric parameters pointed to the importance of the substitution on the aromatic ring for the antileishmanial activity. Apparently a bigger substituent such as bromine (e.g., 3d) may cause some steric hindrance at the molecular interaction level and slight HOMO distribution profile differences resulting in a low antileishmanial profile. Meanwhile, smaller (e.g., chlorine) or no substituents on the aromatic ring may properly interact as in 3e and 3b, respectively (Table 1 and Figure 2).

The 4-(1H-pyrazol-1-yl)benzenesulfonamide derivatives 3a–g were also submitted to an in silico pharmacokinetics properties evaluation. Since good absorption is necessary for oral administration, we analyzed these derivatives according to the rule-of-five developed by Lipinski co-workers (Table 2) [31]. The rule-of-five indicates the theoretical potential for a chemical compound to have good oral bioavailability. The rule states that the most “druglike” molecules present clogP ≤ 5, molecular weight (MW) ≤ 500, number of hydrogen bond acceptors ≤ 10 and donors ≤ 5. Molecules violating more than one of these rules may have bioavailability problems. Our results showed that all compounds of the 4-(1H-pyrazol-1-yl)benzenesulfonamide (3a–g) fulfilled the Lipinski “rule-of-five”. Importantly, according to the theoretical analysis of the lipophilicity (clog P), the most active inhibitors of L. amazonensis and L. infantum were sufficiently hydrophobic for penetrating the biological membranes.

We also compared the drugscore values of these new derivatives with pentamidine, an antileishmanial drug currently in use in the market (Figure 1). The most active compounds showed drugscore values (3b and 3e = 0.48 and 0.46, respectively) similar to pentamidine (0.45) (Figure 1), revealing their potential profile similar to drugs current on the market. Far from establishing absolute results, the molecular modeling data obtained in this work using this series may help to design new benzenesulfonamide-related compounds more activity and/or safety against leishmaniasis.

3. Experimental 3.1. Chemistry 3.1.1. General

The chemicals were obtained from commercial supplies and used without purification, unless otherwise noted. Reactions were routinely monitored by thin-layer chromatography (TLC) on silica gel (60 F-254 Merck) and the products visualized with ultraviolet lamp (254 nm). ¹H- and ¹³C-NMR spectra were determined in DMSO-d₆ and CDCl₃ solutions using a Varian spectrometer, operating at a frequency of 500.0 MH_z for proton and 125.70 MH_z for carbon. Peak positions are given in parts per million (d) from tetramethylsilane as internal standard, and coupling constant values (J) are given in Hz. Signal multiplicities are represented by: s (singlet), d (doublet), t (triplet), q (quadruplet) and m (multiplet). All described products showed ¹H- and ¹³C-NMR spectra consistent with the assigned structures. Infrared (IR) spectra were obtained using spectrometer models 1420, 1600 FT-IR and Spectrum One FT-IR. Samples were examined as potassium bromide (KBr) disks. Melting points are uncorrected and were determined on a Fisatom (430-D) apparatus. All organic solutions were dried over anhydrous sodium sulfate and all organic solvents were removed under reduced pressure on a rotatory evaporator.

3.1.2. General Procedure for the Synthesis of 4-(1<italic>H</italic>-Pyrazol-1-yl)benzenesulfonamides <bold>3a</bold>–<bold>g</bold>

The functionalized amine 2 (0.4 mmol) was added to a solution of the appropriate arylsulfonyl chloride derivative (1.0 mmol) in THF (5 mL) containing triethylamine (0.5 mL). The reaction mixture was stirred for about 2 hours at room temperature, the end of the reaction was observed by TLC. The sulfonamide derivatives 3a–g were isolated by addition of base and subsequent acidification. The products were recrystallized from ethanol, affording the sulfonamide derivatives in good yields [21].

4-(4-Bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)benzenesulfonamide (3a). Brown powder, m.p. = 79–80 °C, Yield: 83%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1162 (SO₂). ¹H-NMR (DMSO-d₆): 2.4 (s, 3H, CH₃, pyrazole), 8.0 (s, 1H, NH), 6.3 (s, 1H, H4 pyrazole), 7.7 (d, 2H, J = 8.8 Hz, H2' and H6' phenyl), 7.3 (d, 2H, J = 8.8 Hz, H3' and H5' phenyl). ¹³C-NMR: 12.3 (CH₃), 133.5 (C₃ pyrazole), 10.2 (C₄ pyrazole), 144.2 (C₅ pyrazole), 140.7 (C_1' phenyl), 139.4 (C_4' phenyl), 121.4 (C_2' and C_6' phenyl), 130.9 (C_3' and C_5' phenyl). Anal. Calc. for C₁₀H₉N₃ (%): C 34.26; H 2.59; N 11.98. Found (%) C 34.18; H 2.41; N 11.75.

4-(4-Bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-N-phenylbenzenesulfonamide (3b). Brown powder, m.p. = 97-100 °C, Yield: 79%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1163 (SO₂). ¹H-NMR (DMSO-d₆): 2.2 (s, 3H, CH₃, pyrazole), 2.3 (s, 3H, CH_3, phenyl), 7.7 (d, 2H, J = 8.8, H2' and H6' phenyl), 7.4 (d, 2H, J = 8.8 Hz, H3' and H5' phenyl), 7.6 (d, 2H, J = 8.8 Hz, H2" and H6" phenyl), 7.2 (dd, 2H, J = 8.8 and 8.3 Hz, H3" and H5" phenyl), 6.2 (s, 1H, H4 pyrazole). ¹³C-NMR: 12.2 (CH₃), 133.5 (C₃ pyrazole), 100.2 (C₄ pyrazole), 144.2 (C₅ pyrazole), 140.4 (C_1' phenyl), 121.6 (C_2' and C_6' phenyl), 131.5 (C_3' and C_5'), 138.5 (C_4' phenyl), 138.0 (C_1" phenyl), 121.5 (C_2" and C_6" phenyl), 130.5 (C_3" and C_5"), 125.1 (C_4" phenyl). Anal. Calc. for C₁₆H₁₃N₃ (%): C 45.03; H 3.07; N 9.85. Found (%) C 44.09; H 3.01; N 9.76.

4-(4-Bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-N-(4methylphenyl)benzenesulfonamide (3c). Brown powder, m.p. = 158–160 °C, Yield: 78%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1162 (SO₂). ¹H-NMR (DMSO-d₆): 2.4 (s, 3H, CH₃), 7.6 (s, 1H, NH), 7.9 (dd, 2H, J = 8.8 Hz, H2' and H6' phenyl), 8.1 (dd, 2H, J = 8.8 Hz, H3' and H5' phenyl). ¹³C-NMR: 12.7 (CH₃), 149.0 (C₃ pyrazole), 96.3 (C₄ pyrazole), 127.1 (C₅ pyrazole), 143.9 (C_1' phenyl), 140.1 (C_4' phenyl), 124.8 (C_2' and C_6' phenyl), 127.1 (C_3' and C_5'). Anal. Calc. for C₁₇H₁₅N₃ (%): C 46.33; H 3.43; N 9.53. Found (%) C 46.27; H 3.34; N 9.41.

4-(4-Bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-N-(4-bromophenyl)benzenesulfonamide (3d). Brown powder, m.p. = 142–144 °C, Yield: 74%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1162 (SO₂). ¹H-NMR (DMSO-d₆): 2.4 (s, 3H, CH₃), 10.5 (s, 1H, NH), 7.9 (d, 2H, J = 8.3 Hz, H2' and H6' phenyl), 8.0 (d, 2H, J = 7.8 Hz, H3' and H5' phenyl), 7.2 (d, 2H, J = 7.8 Hz, H2" and H6" phenyl), 8.0 (dd, 2H, J = 7.8 and 8.3 Hz, H3" and H5" phenyl), 7.2 (t, 1H, 7.8 and 8.3, H4"). ¹³C-NMR: 12.8 (CH₃), 149.2 (C₃ pyrazole), 96.5 (C₄ pyrazole), 126.7 (C₅ pyrazole), 140.8 (C_1' phenyl), 124.7 (C_2' and C_6' phenyl), 129.3 (C_3' and C_5'), 139.1 (C_4' phenyl), 137.4 (C_1" phenyl), 120.5 (C_2" and C_6" phenyl), 128.0 (C_3' and C_5'), 124.5 (C_4' phenyl). Anal. Calc. for C₁₆H₁₂N₃ (%): C 38.01; H 2.39; N 8.31. Found (%) C 37.49; H 2.23; N 8.29.

4-(4-Bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-N-(4-chlorophenyl)benzenesulfonamide (3e). Brown powder, m.p. = −178–179 °C, Yield: 70%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1162 (SO₂). ¹H-NMR (DMSO-d₆): 2.4 (s, 3H, CH₃, pyrazole), 2.6 (s, 3H, CH₃, phenyl) 10.7 (s, 1H, NH), 7.6 (d, 2H, J = 8.8 Hz, H2' and H6' phenyl), 8.0 (d, 2H, J = 8.8 Hz, H3' and H5' phenyl), 7.2 (d, 2H, J = 8.8 Hz, H2" and H6" phenyl), 7.9 (dd, 2H, J = 8.8 and 8.3 Hz, H3" and H5" phenyl). ¹³C-NMR: 12.7 or 12.6 (CH₃ pyrazole or phenyl), 149.2 (C₃ pyrazole), 96.8 (C₄ pyrazole), 136.9 (C₅ pyrazole), 148.2 (C_1' phenyl), 132.2 (C_2' and C_6’ phenyl), 132.5 (C_3' and C_5'). 140.9 (C_4' phenyl), 138.7 (C_1" phenyl), 128.0 (C_2" and C_6" phenyl), 137.9.0 (C_3' and C_5'). 124.7 (C_4' phenyl). Anal. Calc. for C₁₆H₁₂N₃ (%): C 41.67; H 2.62; N 9.11. Found (%) C 41.55; H 2.57; N 9.03.

N-[4-(5-Chloro-3-methyl-1H-pyrazol-1-yl)phenyl]benzenesulfonamide (3f). Brown powder, m.p. = 169–170 °C, Yield: 70%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1162 (SO₂). ¹H-NMR (DMSO-d₆): 2.4 (s, 3H, CH₃, pyrazole), 7.7 (s, 1H, H₄ pyrazole), 10.7 (s, 1H, NH), 7.4 (d, 2H, J = 8.8 Hz, H2' and H6' phenyl), 8.0 (d, 2H, J = 8.8 Hz, H3' and H5' phenyl), 7.2 (d, 2H, J = 8.8 Hz, H2" and H6" phenyl), 7.9 (dd, 2H, J = 8.8 and 8.3 Hz, H3" and H5" phenyl). ¹³C-NMR (d, ppm):12.6 (CH₃ pyrazole), 149.0 (C₃ pyrazole), 96.6 (C₄ pyrazole), 128.6 (C₅ pyrazole), 140.8 (C_1' phenyl), 124.4 (C_2' and C_6' phenyl), 127.9 (C_3' and C_5'). 138.7.9 (C_4' phenyl), 136.3 (C_1" phenyl), 121.9 (C_2" and C_6" phenyl), 129.0 (C_3' and C_5'). 124.9 (C_4' phenyl). Anal. Calc. for C₁₆H₁₃N₃ (%): C 45.03; H 3.07; N 9.85. Found (%) C 49.93; H 2.94; N 9.77.

N-[4-(5-Chloro-3-methyl-1H-pyrazol-1-yl)phenyl]-4-methylbenzenesulfonamide (3g). Brown powder, m.p. = 215–217 °C, Yield: 73%, IR (cm⁻¹): 3051 (CH), 2928 (CH), 1599, 1527 and 1499 (C=C/C=N), 1334 and 1162 (SO₂). ¹H-NMR (DMSO-d₆): 2.3 (s, 3H, CH₃ pyrazole), 7.7 (s, 1H, H₄ pyrazole), 7.6 (d, 2H, J = 8.8, H2' and H6' phenyl), 7.8 (d, 2H, J = 8.8 Hz, H3' and H5' phenyl), 6.9 (d, 2H, J = 8.8 Hz, H2" and H6" phenyl), 7.1 (dd, 2H, J = 8.8 and 8.3 Hz, H3" and H5" phenyl). ¹³C-NMR: 13.6 or 12.7 (CH₃ pyrazol or phenyl), 126.1 (C₃ pyrazole), 168.9 (C₄ pyrazole), 148.5 (C₅ pyrazole), 134.2 (C_1' phenyl), 120.8 (C_2' and C_6' phenyl), 120.9 (C_3' and C_5'), 129.1 (C_4' phenyl), 137.6 (C_1" phenyl), 127.9 (C_2" and C_6" phenyl), 129.6 (C_3' and C_5'). 143.3(C_4" phenyl). Anal. Calc. for C₁₇H₁₅N₃ (%): C 46.33; H 3.43; N 9.53. Found (%) C 46.17; H 3.33; N 9.41.

3.2. Pharmacology 3.2.1. <italic>In Vitro</italic> AntiLeishmanial Drug Assay

Parasites in metacyclic phase (4 × 10⁶ parasites/mL) were incubated with the derivatives (40–160 mg/mL) solubilized in dimethyl sulphoxide (DMSO, Sigma Chemical Co., St. Louis, MO, USA) at 26 °C for 24 h [20]. The results were expressed as IC₅₀/24 h, the concentration of a compound that caused a 50% reduction in survival/viability compared with non-treated culture. Pentamidine was used as reference drug and all tests were carried out in triplicate. Promastigotes of L. amazonensis (MHOM/BR/77/LTB0016 strain) and L. infantum (syn. chagasi) (MCAN/BR/97/P142 strain) were grown in Schneider’s insect medium (Sigma) at 26 °C in pH 7.2 supplemented with 10–20% (v/v) heat-inactivated fetal calf serum.

3.2.2. <italic>Animals</italic>

The BALB/c mice from Laboratory Animals Nucleus (UFF) were sacrificed to obtain peritoneal cells and for both infection and isolation of Leishmania. The protocol assays was approved by the Institutional Committee of the Center for Biological Evaluation and Care of Research Animals (CEUA-UFF).

3.2.3. <italic>In Vitro</italic> Cytotoxicity

BALB/c mice peritoneal cavity cells (4 × 10⁵cells/well) were incubated with the derivatives (10, 20, 40 and 80 µg/mL) in 96 wells plate for 24 h in cold RPMI 1640 medium, supplemented with 1 mmol·L⁻¹L-glutamine, 1 mol·L⁻¹ HEPES, penicillin G (10⁵ IU·L⁻¹) and streptomycin sulfate (0.10 g·L⁻¹) at 37 °C in a humidified 5% CO₂ atmosphere. After that, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, MTT (Sigma) was added and the reaction was interrupted with DMSO after 2 h. The results were determined in 540 nm by using a MicroQuant spectrophotometer (Biotek-Instrument Inc., Winooski, VT, USA). All assays were repeated at least four times in quadruplicate. The cytotoxicity profile was expressed as CC₅₀/24 h, the concentration of a compound that caused cytotoxicity compared to non-treated cultures [6]. Index of selectivity (IS) was defined as the ratio of the CC₅₀ value on the macrophage to the IC₅₀ value on the L. amazonensis or L. infantum strains (promastigotes).

3.2.4. Molecular Modeling Studies:

All molecular computations were performed using SPARTAN’08 (Wavefunction Inc. Irvine, CA, USA) as described elsewhere [20]. The theoretical studies of druglikeness and drugscore and ADMET were performed using Osiris Property Explorer (http://www.organic-chemistry.org/). Briefly the structures were optimized to a local minimum and the equilibrium geometry obtained in vacuum using RM1 semi-empirical methods. Subsequently, molecules were submitted to a single-point energy ab initio calculation, at the 6-31G* level, to calculate some stereoelectronic properties and perform the SAR studies. Thus, we calculated for all compounds best conformation the values of HOMO (Highest Occupied Molecular Orbital) and LUMO (Lowest Unoccupied Molecular Orbital) energies and density isosurface, molecular weight (MW), molecular surface area and volume, polar surface area (TPSA), dipole moment and lipophilicity using the same program.

The druglikeness value is calculated based on the occurrence frequency of each fragment is determined within the collection created by shredering 3300 traded drugs as well as 15,000 commercially available chemicals (Fluka Chemical Co., Buchs, Switzerland) yielding a complete list of all available fragments. In this case, positive values point out that the molecule contains predominantly the better fragments, wich are frequently present in commercial drugs but not in the non-druglike collection of fluka compounds. The drugscore combines druglikeness, clogP, logs, molecular weight and toxicity risks in one handy value that may be used to judge the drug potential of a compound.

3.2.5. Statistical Analysis

Each experiment was done three to four times, in triplicate. Significance was determined using a non-paired t Student test and Mann–Whitney analyses and p < 0.05.

4. Conclusions

In summary, a novel family of 4-(1H-pyrazol-1-yl)benzenesulfonamide derivatives 3a–g has been synthesized and evaluated against Leishmania spp. The antileishmanial data showed a better active profile for 3b–e on promastigote forms of L. infantum and L. amazonensis, close to that of the reference drug pentamidine. The cytotoxic tests using murine adherent peritoneal cells pointed out that 3b and 3e had better IC₅₀ values than pentamidine. Molecular modeling evaluation indicated that changes in electronic regions, orientation as well as lipophilicity of the derivatives were areas to improve the interaction with the parasitic target. The biological and theoretical data reinforced the potential of these molecules as an alternative option for testing against resistant Leishmania strains and/or for further synthetic and biological exploration for the development of better antileishmanial drugs.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

This work is supported by grants from CAPES, CNPq, FAPERJ, FIOCRUZ, PROPPI/UFF and fellowships from CAPES, CNPq and PIBIC/UFF, Brazil.

References 1.

Alvar

Vélez

Bern

Herrero

Desjeux

Cano

Jannin

den Boer

the WHO Leishmaniasis Control Team

Leishmaniasis worldwide and global estimates of its incidence

PLoS One 2012 7 e35671

10.1371/journal.pone.0035671

22693548

2. World Health Organization (WHO) Organization Control of the Leishmaniases; World Health Organization Technical Report 2010, Number 949 WHO

Geneva, Switzerland

2010 1 186 3.

Leon

L.L.

Barral

Machado

G.M.C.

Grimaldi

Jr.

Antigenic differences among Leishmania amazonensis isolates and their relationship clinical forms of the disease

Mem. Inst. Oswaldo. Cruz 1992 87 229 234

1284990

Croft

S.L.

Olliaro

Leishmaniasis chemotherapy-challenges and opportunities

Clin. Microbiol. Infect. 2011 17 1478 1483

10.1111/j.1469-0691.2011.03630.x

Richard

J.V.

Werbovetz

K.A.

New antileishmanial candidates and lead compounds

Curr. Opin. Chem. Biol. 2010 14 447 455

10.1016/j.cbpa.2010.03.023

Charret

K.S.

Rodrigues

R.F.

Bernardino

A.M.

Gomes

A.O.

Carvalho

A.V.

Canto-Cavalheiro

M.M.

Leon

Amaral

V.F.

Effect of the oral treatment with pyrazole carbohydrazides derivatives in the murine infection by Leishmania amazonensis

Am. J. Trop. Med. Hyg. 2009 80 568 573

19346377

Kobets

Grekov

Lipoldova

Leishmaniasis: Prevention, parasite detection and treatment

Curr. Med. Chem. 2012 19 1443 1474

10.2174/092986712799828300

Singh

Sundar

Leishmaniasis: Vaccine candidates and perspectives

Vaccine 2012 30 3834 3842

10.1016/j.vaccine.2012.03.068

Vanaerschot

Doncker

Rijal

Maes

Dujardin

J.-C.

Decuypere

Antimonial resistence in Leishmania donovani is associated with increased in vivo parasite burden

PLoS One 2011 6 e23120

10.1371/journal.pone.0023120

21829701

10. Ministry of Health of Brazil

Casos confirmados de leishmaniose visceral Segundo UF de residências, Brasil grandes regiões e unidades federadas

2008

(accessed on 31 October 2011)

Available online:http://portal.saude.gov.br/arquivos/pdf/casos_lv.pdf 11.

Bernardino

A.M.R.

Gomes

A.O.

Charret

K.S.

Machado

G.M.

Canto-Cavalheiro

M.M.

Leon

L.L.

Amaral

V.F.

Synthesis and leishmanial activities of 1-(4-X-phenyl)-N'-[(4-Y-phenyl)methyllene]-1H-pyrazole-4-carbohydrazides

Eur. J. Med. Chem. 2006 41 80 87

10.1016/j.ejmech.2005.10.007

12.

Santos

M.S.

Gomes

A.O.

Bernardino

A.M.R.

Souza

M.C.

Khan

M.A.

Brito

M.A.

Castro

H.C.

Abreu

P.A.

Rodrigues

C.R.

Léo

R.M.M.

Synthesis and antileishmanial activity of new 1-aryl-1H-pyrazole-4-carboximidamides derivatives

J. Braz. Chem. Soc. 2011 22 352 358

10.1590/S0103-50532011000200022

13.

Santos

M.S.

Oliveira

M.L.V.

Bernardino

A.M.R.

Léo

R.M.

Amaral

V.F.

Carvalho

F.T.

Leon

L.L.

Canto-Cavalheiro

M.M.

Synthesis and antileishmanial evaluation of 1-aryl-4-(4,5-dihydro-1H-imidazol-2-yl)-1H-pyrazole derivatives

Bioorg. Med. Chem. Lett. 2011 21 7451 7454

10.1016/j.bmcl.2011.09.134

22055204

14.

Fustero

Sánchez-Reselló

Barrio

Simón-Fuentes

From 2000 to id 2010: A fruitful decade for the synthesis of pyrazoles

Chem. Rev. 2011 111 6984 7034

10.1021/cr2000459

15.

Patel

N.B.

Patel

J.N.

Lilakar

J.D.

Sulfonamides of 2-[(2,6-dichlorophenyl)amino]phenyl acetoxyacetic acid and their antibacterial studies

Acta Pol. Pharm. 2010 67 351 359

20635530

16.

Loh

Vozzolo

Mok

Lee

C.C.

Fitzmaurice

R.J.

Caddick

Fassati

Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides

Chem. Biol. Drug Des. 2010 75 461 474

10.1111/j.1747-0285.2010.00956.x

17.

Silva

L.E.

Joussef

A.C.

Pacheco

L.K.

Silva

D.G.

Steindel

Rebelo

R.A.

Synthesis and in vitro evaluation of leishmanicidal and trypanocidal activities of N-quinolin-8-yl-arylsulfonamides

Bioorg. Med. Chem. 2007 15 7553 7560

10.1016/j.bmc.2007.09.007

18.

Bilbao-Ramos

Galiana-Roselló

Dea-Ayuela

M.A.

González-Alvarez

Veja

Rolón

Pérez-Serrano

Bolás-Fernández

González-Rosende

M.E.

Nuclease activity and ultrastructural effects of new sulfonamides with anti-leishmanial and trypanocidal activities

Parasitol. Int. 2012 61 604 613

10.1016/j.parint.2012.05.015

19.

Dea-Ayuela

M.A.

Castillo

Gonzalez-Alvarez

Veja

Rolón

Bolás-Fernández

Borrás

González-Rosende

M.E.

In vivo and in vitro anti-leishmanial activities of 4-nitro-N-pyrimidin and N-pyrazin-2-ylbenzenesulfonamides, and N²-(4-nitrophenyl)-N¹-Propylglycinamide

Bioorg. Med. Chem. 2009 17 7449 7456

10.1016/j.bmc.2009.09.030

20.

Souza

A.M.T.

Castro

H.C.

Brito

M.A.

Andrighetti-Fröhner

C.R.

Magalhães

Oliveira

K.N.

Gaspar-Silva

Pacheco

L.K.

Joussef

A.C.

Steindel

Leishmania amazonensis growth inhibitors: Biological and theoretical features of sulfonamide 4-methoxychalcone derivatives

J. Curr. Microbiol. 2009 59 374 379

10.1007/s00284-009-9447-2

21.

Souza

T.M.

Morais-Braga

M.F.

Saraiva

A.A.

Rolón

Veja

de Arias

A.R.

Costa

J.G.

Menezes

I.R.

Coutinho

H.D.

Evaluation of the anti-Leishmania activity of ethanol extract and fractions of the leaves from Pityrogramma calomelanos (L.) link

Nat. Prod. Res. 2012 8

10.1080/14786419.2012.686911

22.

Machado

Pires

Dinis

A.M.

Santos-Rosa

Alves

Salgueiro

Cavaleiro

Sousa

M.C.

Monoterpenic aldehydes as potential anti-Leishmania agents: Activity of Cymbopogon citratus and citral on L. infantum, L. tropica and L. major

Exp. Parasitol. 2012 130 223 231

10.1016/j.exppara.2011.12.012

22227102

23.

De Carvalho

G.S.

Machado

P.A.

de Paula

D.T.

Coimbra

E.S.

da Silva

A.D.

Synthesis, Cytotoxicity, and Antileishmanial Activity of N,N'-Disubistituted Ethylenediamine and Imidazolidine Derivatives

Sci. World. J. 2010 10 1723 1730

10.1100/tsw.2010.176

24.

Silveira

F.T.

Lainson

Crescente

J.A.

de Souza

A.A.

Campos

M.B.

Gomes

C.M.

Laurenti

M.D.

Corbett

C.E.

A prospective study on the dynamics of the clinical and immunological evolution of human Leishmania (L.) infantum chagasi infection in the Brazilian. Amazon region

Trans. R. Soc. Trop. Med. Hyg. 2010 104 529 535

10.1016/j.trstmh.2010.05.002

20538310

25.

Free Patent On Line. Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them

(accessed on 15 January 2006)

Available online:http://www.freepatentsonline.com/6908947.html 26.

Andrighetti-Frohner

C.R.

de Oliveira

K.N.

Gaspar-Silva

Pacheco

L.K.

Joussef

A.C.

Steindel

Simões

C.M.

de Souza

A.M.

Magalhaes

U.O.

Afonso

I.F.

Synthesis, biological evaluation and SAR of sulfonamide 4-methoxychalcone derivatives with potential antileishmanial activity

Eur. J. Med. Chem. 2009 44 755 763

10.1016/j.ejmech.2008.04.016

18554753

27.

Parise-Filho

Pasqualoto

K.F.

Magri

F.M.

Ferreira

A.K.

da Silva

B.A.

Damião

M.C.

Tavares

M.T.

Azevedo

R.A.

Auada

A.V.

Polli

M.C.

Dillapiole as Antileishmanial Agent: Discovery, Cytotoxic Activity and Preliminary SAR Studies of Dillapiole Analogues

Arch. Pharm. (Weinheim) 2012 19

10.1002/ardp.201200212

28.

Canto-Cavalheiro

M.M.

Echevarria

Araujo

C.A.

Bravo

M.F.

Santos

L.H.

Jansen

A.M.

Leon

L.L.

The potential effects of new synthetic drugs against Leishmania amazonensis and Trypanosoma cruzi

Microbios 1997 90 51 60

9301071

29.

Schetz

J.A.

Structure-Activity Relationships

xPharm: The Comprehensive Pharmacology Reference 2007 1 12 30.

Lewis

D.F.V.

Frontier orbitals in chemical and biological activity: Quantitative relationships and mechanistic implications

Drug Metab. Rev. 1999 31 755 816

10.1081/DMR-100101943

31.

Lipinski

C.A.

Lombardo

Dominy

B.W.

Feeney

Experimental and computacional approaches to estimate solubility and permeability in drug discovery and development settings

J. Adv. Drug Deliv. Rev. 2001 46 3 26

10.1016/S0169-409X(00)00129-0

Sample Availability: Not available.